跳至主要内容
临床试验/NCT01341132
NCT01341132Unknown不适用

Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents

San Francisco Veterans Affairs Medical Center1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2011年5月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
75
试验地点
1

研究概览

简要总结

This study aims to determine whether or not gadoxetate disodium (Eovist) enhanced magnetic resonance imaging (MRI) has a higher sensitivity for detecting hepatocellular carcinoma (Liver Cancer) comparison to multi-detector computed tomography (CT).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Alpha-feto protein > 400 ng / mL or
  • prior ultrasound with mass suspicious for hepatic malignancy or.
  • clinical risk of hepatocellular carcinoma or
  • prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma

排除标准

  • Glomerulo-filtration rate < 50 mL/ min/1.73 m2 based on a creatinine measurement within three months of the MR study
  • Previous diagnosis of hepatic malignancy
  • Any conditions that would discount the ability to have an MRI scan

研究者

发起方
San Francisco Veterans Affairs Medical Center
申办方类型
Fed

研究点 (1)

Loading locations...

相似试验